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ABSTRACT 
 
Introduction: Metastasis from solid tumours is associated with significant morbidity 
and mortality, and is the leading cause of cancer-related deaths. Voltage-gated 
sodium channels (VGSCs) are drug targets for the treatment of epilepsy. VGSCs are 
also present in cancer cells, where they regulate metastatic cell behaviours, including 
cellular movement and invasion. Treating cancer cells with the VGSC-inhibiting 
anticonvulsant phenytoin reduces cellular invasion and migration. Together, these 
suggest that VGSCs may be useful targets for inhibiting metastasis. The purpose of 
this study is to test the hypothesis that use of VGSC-inhibiting drugs will reduce 
metastasis, and therefore increase survival time in cancer patients. 
 
Methods and analysis: A cohort study based on primary care data from the 
QResearch database will include patients with one of three common tumours: breast, 
bowel, and prostate. The primary outcome will be overall survival from date of cancer 
diagnosis. Cox proportional hazards regression will be used to compare the survival 
of cancer patients taking VGSC-inhibiting drugs (including anticonvulsants and Class 
I antiarrhythmic agents) with cancer patients not exposed to these drugs, adjusting 
for age and sex.  Exposure to VGSC-inhibiting drugs will be defined as having at 
least one prescription for these drugs prior to cancer diagnosis.  High and low 
exposure groups will be identified based on length of use. A number of sensitivity and 
secondary analyses will be conducted. 
 
Ethics and dissemination: The protocol has been independently peer-reviewed and 
approved by the QResearch Scientific Board. The project has also been approved by 
the University of York Ethical Review Process. The results will be presented at 
international conferences and published in an open access peer-reviewed journal, in 
accordance with the STROBE criteria. 
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STRENGTHS AND LIMITATIONS OF THIS STUDY 
 
• Primary care research data 
• Large sample size and statistical power 
• Planned sensitivity analyses 
• Prescription-based study 
• No direct information on metastasis, estimation is via overall survival 
• Some variables of interest may be missing and/or poor quality in GP data 
 
INTRODUCTION 
 
Bowel, breast and colon cancer are common cancers, which if diagnosed late have 
often already spread to secondary sites (metastasised). Metastasis is associated with 
significant morbidity and mortality. Metastasis is the leading cause of cancer-related 
deaths[1] because a metastatic cancer is rarely amenable to cure, and interventions 
are largely limited to palliation.[2] Therefore, there is an urgent need to identify and/or 
develop new metastasis prevention strategies. 
 
The classical role of voltage-gated sodium channels (VGSCs) is to transmit action 
potentials in electrically excitable cells, e.g. neurons and cardiomyocytes.[3] VGSCs 
also regulate neuronal growth and migration.[4-7] Related to these functions, VGSCs 
are clinical targets for a range of disorders, including epilepsy, cardiac arrhythmias, 
neuropathic pain and depression.[8] The mode of action of a number of commonly 
prescribed antiepileptic drugs (anticonvulsants), including phenytoin, lamotrigine, 
carbamazepine and valproate, is to inhibit VGSCs.[9] Similarly, the principal mode of 
action of Class I antiarrhythmic drugs is to inhibit VGSCs.[10] 
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More recently, VGSCs have been identified in cells from a number of major cancers, 
including carcinomas of the breast, prostate and colon.[11 12] In these cells, VGSCs 
promote in vitro cellular behaviours that are associated with metastasis, including 
migration and invasion.[13-18] Overexpression of the VGSC β1 subunit in breast 
cancer cells increases metastasis in mice.[19-21] The VGSC-inhibiting 
anticonvulsant phenytoin significantly reduces migration and invasion of metastatic 
breast and prostate cancer cells in vitro.[22 23] Together, these data suggest that 
VGSCs may be useful targets for anti-metastatic therapy, and that VGSC-inhibiting 
drugs may improve survival from certain cancers.[11 24] Although the effect of 
several anticonvulsants on risk of developing various cancers has been studied 
before (reviewed in[25]), the relationship between VGSC-inhibiting drugs and survival 
of cancer patients has not been investigated. 
 
The purpose of this study is to test the hypothesis that use of VGSC-inhibiting drugs 
will predict increased time to metastasis and thus improved survival time in cancer 
patients. The objectives are to investigate: 
• The relationship between use of all VGSC-inhibiting (anticonvulsant and 
Class I antiarrhythmic) drugs and overall survival of cancer patients. We will 
focus on carcinomas of the breast, colon and prostate because they are the 
most common and VGSC expression has been extensively studied in these 
tumours.[11 13-17 26-29] 
• The relationship between use of all VGSC-inhibiting drugs and cancer specific 
survival. 
• The relationship between individual VGSC-inhibiting drugs and overall 
survival. 
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There are no systematic reviews exploring this area and we are addressing this gap 
by conducting a review concurrent to this study [PROSPERO registration number 
CRD42014013574]. 
 
METHODS AND ANALYSIS 
 
Data source and sample selection 
 
This study will use general practice data accessed from QResearch 
(http://www.qresearch.org), a large consolidated database derived from the 
anonymised health records of over 13 million patients from 753 general practices 
(representing around 7% of UK practices). QResearch data are collected from the 
EMIS GP computer system and have been validated using other sources and shown 
to yield similar results to other databases, e.g. the Clinical Practice Research 
Datalink (CPRD).[30 31] QResearch has been used previously to study associations 
between cancer and prescription information.[30] 
 
An open cohort of 100,000 patients (aged 30 years or older) with a diagnosis of 
breast, colorectal or prostate cancer will be identified who were registered with a 
QResearch practice during the study period between 1st January 1998 and 31st 
December 2013. This will include all those cancer patients in the database who have 
a prescription of one of the index drugs recorded before their date of cancer 
diagnosis (Table 1).[32] The remaining patients will be randomly selected controls.  
Time from date of diagnosis to death will be investigated and data will be right-
censored in patients who are still alive at the end of the study period. Cancer 
diagnoses will be based on Read code information (available online at 
clinicalcodes.org/medcodes/article/17/). 
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Table 1. Voltage-gated Na+ channel-inhibiting drugs 
Drug/derivative Alternative names Classification British National 
Formulary (BNF) 
section[32] 
Carbamazapine, 
eslicarbazepine, 
oxcarbazepine 
Arbil, Carbagen 
SR, Epimaz, 
Inovelon, Tegretol, 
Teril, Timonil, 
Trileptal, Zebinix 
Anticonvulsant 4.2.3, 4.7.3, 4.8.1 
Disopyramide Dirythmin, Isomide, 
Rythmodan 
Class Ia 
antiarrhythmic 
2.3.2 
Flecainide Tambocor Class Ic 
antiarrhythmic 
2.3.2 
Lacosamide Vimpat Anticonvulsant 4.8.1 
Lamotrigine Lamictal Anticonvulsant 4.8.1 
Lidocaine Lignocaine, 
Xylocard 
Class Ib 
antiarrhythmic 
2.3.2, 15.2 
Mexiletine Mexitil Class Ib 
antiarrhythmic 
2.3.2 
Moracizine Ethmozine 
 
Class Ic 
antiarrhythmic 
- 
Phenytoin, 
fosphenytoin 
Epanutin, Pentran Anticonvulsant, 
Class Ib 
antiarrhythmic 
4.7.3, 4.8.1, 4.8.2 
Procainamide Pronestyl Class Ia 
antiarrhythmic 
2.3.2 
Propafenone Arythmol Class Ic 2.3.2 
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antiarrhythmic 
Quinidine Kiditard 
 
Class Ia 
antiarrhythmic 
- 
Ranolazine Ranexa Antianginal 2.6.3 
Riluzole Rilutek Treatment for 
amyotrophic lateral 
sclerosis 
4.9.3 
Tocainide Tonocard Class Ib 
antiarrhythmic 
- 
Topiramate Topamax Anticonvulsant 4.7.4, 4.8.1 
Valproic acid, 
sodium valproate 
Convulex, 
Depakote, Epilim, 
Epival, Episenta, 
Orlept 
Anticonvulsant 4.2.3, 4.7.4, 4.8.1 
 
Exclusions 
 
Temporary residents and patients registered with QResearch within 12 months of 
data extraction will be excluded. Cases without diagnosis of one of the three index 
cancers (breast, colorectal, or prostate cancer) will be excluded. Patients with 
anomalous, incorrect or infeasible dates will be excluded, e.g., dates of cancer 
diagnoses recorded before birth or after death.  We shall assume that dates of birth 
and death are correct.  Any patient with a date of diagnosis that indicates they were 
younger than 25 at the time of diagnosis will be excluded as it is unlikely a person of 
that age would get one of these three cancers. 
 
Exposure 
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A participant will be considered as exposed if they have had at least one prescription 
for one of the index drugs. Assuming continuous treatment use between 
prescriptions, we will identify two exposure groups: a low exposure group (less than 6 
months worth of prescriptions) and a moderate to high exposure group (six months or 
more prescriptions). The exposed groups, separately and in combination, will be 
compared with the control group (cases without any prescription for one of the index 
drugs). Patients with one prescription for a drug that would have been used as a local 
anaesthetic, e.g. lidocaine, will be excluded. 
 
Outcome measures 
 
Metastasis is estimated to be responsible for 90% of deaths from solid tumours.[33] 
However, metastasis itself is not reliably recorded in GP data and so the primary 
outcome measure will be overall survival following cancer diagnosis as a proxy for 
metastasis. Secondary outcome measures will be cancer-specific survival for each 
index type of cancer and overall survival across each drug, numbers permitting. 
 
Confounding factors 
 
Data on the following confounders will be requested: age, gender, alcohol 
consumption, smoking status, body mass index (BMI) and ethnicity.  Data on alcohol, 
smoking and BMI are routinely collected and as such a single patient may have 
multiple recorded observations for these variables assessed over time.  We will 
consider the observations measured at the closest date before the date of cancer 
diagnosis, based on appropriate Read codes (available online at 
clinicalcodes.org/medcodes/article/17/). The patients will be categorised as follows: 
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• Alcohol consumption[34] categorised as: Non/trivial drinker (<1unit/day), Light 
drinker (1-2units/day), Moderate-very heavy drinker(3+units/day) and Not 
recorded/known. 
• Smoking status[35] categorised as: Ex-smoker, Smoker, Non-smoker, and 
Not recorded/known. 
• BMI,[36] categorised as Underweight (<18.5), Normal range [18.5-25), 
Overweight [25, 30), Obese (30+) and Not recorded/known. 
• Ethnicity[37] categorised according to the groupings used in the 2011 UK 
census: White; Mixed/Multiple ethnic groups; Asian/Asian British; 
Black/African/Caribbean/Black British; Other Ethnic group.  We shall also 
include a ‘Not recorded/known’ category. 
 
Sample size calculation 
 
Up to 100,000 eligible cases will be used, which is the maximum sample size that will 
be released by QResearch. At breast cancer diagnosis, approximately 6% of patients 
present with metastatic lesions, with bone being the most common site.[38] Of 
patients presenting without bone metastasis at diagnosis, 3.6% subsequently 
develop metastases.[39 40] The majority (90%) of metastases will lead to death.[33] 
Pharmacological blockade of VGSCs inhibits invasion of breast, colorectal and 
prostate cancer cells in vitro by 25-50%.[13 15 22 23] Therefore, assuming 3.6% of 
cancer diagnoses lead to a metastasis and most of these to death, with standard 
significance level alpha = 5% and power = 90%, we would require 4248 in the 
exposed group to detect a fall of 25% in the metastasis (or death) rate and 928 to 
detect a fall of 50%.  This is based on 20 comparison patients per exposed patient, 
but this ratio is not critical.  If we include 6% with a metastasis present at initial 
diagnosis, these numbers fall to 1503 and 330. 
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The prevalence of epilepsy is estimated to be 1%.[41] Together, the most commonly 
used VGSC-inhibiting anticonvulsants, phenytoin, lamotrigine, carbamazepine and 
valproate, account for >82% of all antiepileptic drug use.[42] By contrast, Class I 
antiarrhythmic drug use has been considerably less common: <5% in patients with 
cardiac arrhythmia.[43] Thus, using these data as a guide, we might reasonably 
anticipate that around 0.8% of cancer patients would be using one of these VGSC-
inhibiting drugs. To meet our largest target sample size, 4248, we would therefore be 
looking for a sample that contained 530,000 people with a diagnosis of one of the 
target cancers.  To meet the lower target of 928, we would require 116,000 
diagnoses.  Given that we are studying deaths rather than metastases per se, we will 
be unable to distinguish between metastases present at diagnosis and detected 
subsequently. Therefore, if we include 6% assumed to have a metastasis present at 
initial diagnosis, we would require 187,875 and 41,250 diagnoses to detect falls in 
metastasis of 25% and 50% respectively. 
 
According to Cancer Research UK,[44] the lifetime risk in 2010 for the four major 
cancer sites was almost 13% (female breast), 6% (female lung), 8% (male lung), 6% 
(female bowel including anus), 7% (male bowel including anus) and 13% (prostate).  
Hence for our chosen sites, we expect approximately 21% of women and 20% of 
men to experience a positive diagnosis at some time.  We will not have lifetime data 
for many in the database, but we might anticipate that 10% of a database sample 
would have a history of one of these sites.  Thus the Qresearch database of 13 
million people is large enough to achieve our largest sample target. 
 
Statistical analysis 
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Analysis will be conducted in Stata v13, using two-sided significance at the 5% level.  
For each Cox model, only the patients with complete data for each of the covariates 
controlled for in the model will be included in the analysis. 
 
Descriptive summaries 
 
The characteristics of the comparison groups will be described using summary 
statistics. Categorical data will be presented as frequency and percentage, and 
continuous variables will be summarised using descriptive statistics (mean, standard 
deviation, median, 1st and 3rd quartiles, minimum and maximum).  The flow of 
patients in the QResearch database will be presented in a diagram. 
 
Primary analysis 
 
The primary analysis will compare the combined exposure group to the control group.  
For each group, the distribution of time from diagnosis of cancer to death will be 
described using Kaplan-Meier survival estimates.  Kaplan-Meier survival curves will 
be presented for the two groups.  The statistical equivalence of the two curves will be 
tested using the log-rank test.  Right censoring will occur if the patient is still alive at 
the end of the study period (31st December 2013).  Median time to death, with a 95% 
confidence interval (CI) will be presented. If the estimated survivor function is greater 
than 0.5 throughout the study it will not be possible to estimate the median 
survival time and other percentiles survival values (i.e. 90%, 80%, 75%, as 
appropriate) will be presented. 
 
We will compare the survival of exposed cases with control cases from time of 
diagnosis of one of the three index cancers using a Cox Proportional Hazards 
regression model. The endpoint will be all cause mortality.  We will adjust the Cox 
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model for type of cancer (breast, bowel or prostate), gender and age at diagnosis.  
Age will be included with both a linear and quadratic term (age + age2).  We will 
assume that all included patients are receiving the most appropriate standard 
treatment for their disease, so we will not adjust for cancer-treating drug intake.  
Hazard ratios will be presented with p-values and 95% confidence intervals.  
 
Cox regression assumes that the proportional hazards model applies.  To assess 
this, we shall plot –log(-log(S(t))) against log(time), where S(t) is the survivor function 
at time t.  The curves for the two groups should be parallel.  We will also consider a 
chi-squared test of the Schoenfeld residuals to assess the null hypothesis of no 
relationship between the hazards in each group.  If the assumptions are not met, we 
shall try to investigate why this is. 
 
Sensitivity analysis 
 
We will repeat the primary analysis, but adjust the Cox model, in turn, for 
confounding variables: ethnicity, body mass index, smoking and alcohol 
consumption. 
 
Secondary analyses 
 
Each of the following secondary end points will be analysed like the primary outcome 
(unless indicated) with identical censoring strategy:  
• If cancer type proves to be a significant predictor in the primary model then 
we will consider cancer specific survival 
• Survival of Low exposure group compared with control group 
• Survival of High exposure group compared with control group 
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• Survival of combined exposure group and control group with outcome of time 
to death from first diagnosis of any cancer, since some patients may have a 
diagnosis of another cancer before one of breast, bowel or prostate (a 
category for ‘Other’ will be included in the covariate for type of cancer) 
• Survival of patients dependent on the main drug class that they are exposed 
to (numbers permitting). 
 
ETHICS AND DISSEMINATION 
 
This protocol has been independently peer-reviewed by the QResearch Scientific 
Board. It has also been approved by the University of York Ethical Review Process. 
Only the authors will have access to the data during the study, in order to guarantee 
confidentiality of patient information. An article detailing the results of the study will 
be submitted for publication in an international peer-reviewed journal, in accordance 
with the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) criteria.[45] The full statistical analysis will be available from the authors 
after publication of the results. 
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